Skip to main content

Table 3 Multivariable mixed-effect regression associated subgroup phMDA with worse 5-year functionality (HAQ) trajectory than plMDA subgroup

From: Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group

HAQ multivariable analysis Coefficient 95% CI p value
Group phMDA (vs plMDA) + 0.26 + 0.17 to + 0.36 p < 0.0001*
Gender female (vs male) + 0.12 + 0.01 to + 0.24 p = 0.04*
Age (per year) + 0.009 + 0.005 to + 0.013 p < 0.0001*
Disease duration (per year) + 0.002 − 0.004 to + 0.007 p = 0.543
Time 3–9 months (vs baseline) − 0.200 − 0.287 to − 0.114 p < 0.0001*
Time 9–15 months (vs baseline) − 0.285 − 0.373 to − 0.196 p < 0.0001*
Time 15–21 months (vs baseline) − 0.291 − 0.378 to − 0.204 p < 0.0001*
Time 21–27 months (vs baseline) − 0.279 − 0.369 to − 0.190 p < 0.0001*
Time 27–33 months (vs baseline) − 0.342 − 0.444 to − 0.240 p < 0.0001*
Time 33–42 months (vs baseline) − 0.308 − 0.392 to − 0.225 p < 0.0001*
Time 42–54 months (vs baseline) − 0.313 − 0.396 to − 0.231 p < 0.0001*
Time 54–60 months (vs baseline) − 0.380 − 0.463 to − 0.297 p < 0.0001*
  1. *Variable is associated significantly with patients’ 5-year functionality (HAQ) course (p < 0.05 significance threshold)
  2. Regression coefficient that represents increase (+) or decrease (−) in 5-year functionality (HAQ) course associated with the variable (category membership for categorical variable or unit increase for continuous variable)
  3. Efficiency of multivariable analysis: RMSE (Root mean square error) = 0.366, R2 (R-squared) = 0.538
  4. plMDA persistent lower-moderate disease activity group; phMDA persistent higher-moderate disease activity group
\